# Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

> **NCT02840721** · PHASE2 · COMPLETED · sponsor: **Telavant, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** PF-06480605

## Key facts

- **NCT ID:** NCT02840721
- **Lead sponsor:** Telavant, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-26
- **Primary completion:** 2018-05-31
- **Final completion:** 2018-08-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02840721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02840721, "Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT02840721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*